Proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors: Shaping the future after the further cardiovascular outcomes research with PCSK9 inhibition in subjects with elevated risk (FOURIER) trial

被引：17
|
作者：
Katsiki, Niki [1 ]
Athyros, Vasilios G. [1 ]
Mikhailidis, Dimitri P. [2 ]
Mantzoros, Christos [3 ]
机构：
[1] Aristotle Univ Thessaloniki, Hippocrat Hosp, Med Sch, Propedeut Dept Internal Med 2, Thessaloniki, Greece
[2] UCL, Royal Free Hosp Campus, Med Sch, Dept Clin Biochem, London, England
[3] Harvard Med Sch, Beth Israel Deaconess Med Ctr, Dept Internal Med, Div Endocrinol Diabet & Metab, Boston, MA USA
来源：
METABOLISM-CLINICAL AND EXPERIMENTAL | 2017年 / 74卷
关键词：
GENETIC-VARIANTS; REDUCING LIPIDS; STATIN THERAPY; MANAGEMENT; EVOLOCUMAB; EFFICACY; SAFETY; DYSLIPIDEMIA; ASSOCIATION; ALIROCUMAB;
D O I：
10.1016/j.metabol.2017.04.007
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：43 / 46
页数：4
相关论文
共 50 条
  • [31] Nonstatins and Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors: Role in Non-Familial Hypercholesterolemia
    Robinson, Jennifer G.
    PROGRESS IN CARDIOVASCULAR DISEASES, 2016, 59 (02) : 165 - 171
  • [32] Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. A new drug class for the treatment of hypercholesterolemia
    Martinez de Victoria, Emilio Ortega
    ENDOCRINOLOGIA DIABETES Y NUTRICION, 2017, 64 (07): : 341 - 344
  • [33] Rationale and design of the Further cardiovascular OUtcomes Research with PCSK9 Inhibition in subjects with Elevated Risk trial
    Sabatine, Marc S.
    Giugliano, Robert P.
    Keech, Anthony
    Honarpour, Narimon
    Wang, Huei
    Liu, Thomas
    Wasserman, Scott M.
    Scott, Robert
    Sever, Peter S.
    Pedersen, Terje R.
    AMERICAN HEART JOURNAL, 2016, 173 : 94 - 101
  • [34] Proprotein convertase subtilisin/kexin type 9 (PCSK9): From structure-function relation to therapeutic inhibition
    Tibolla, G.
    Norata, G. D.
    Artali, R.
    Meneghetti, F.
    Catapano, A. L.
    NUTRITION METABOLISM AND CARDIOVASCULAR DISEASES, 2011, 21 (11) : 835 - 843
  • [35] Stroke Prevention With the PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Evolocumab Added to Statin in High-Risk Patients With Stable Atherosclerosis
    Giugliano, Robert P.
    Pedersen, Terje R.
    Saver, Jeffrey L.
    Sever, Peter S.
    Keech, Anthony C.
    Bohula, Erin A.
    Murphy, Sabina A.
    Wasserman, Scott M.
    Honarpour, Narimon
    Wang, Huei
    Lira Pineda, Armando
    Sabatine, Marc S.
    STROKE, 2020, 51 (05) : 1546 - 1554
  • [36] Reduction of low density lipoprotein- cholesterol and cardiovascular events with proprotein convertase subtilisin-kexin type 9 (PCSK9) inhibitors and statins: an analysis of FOURIER, SPIRE, and the Cholesterol Treatment Trialists Collaboration
    Ference, Brian A.
    Cannon, Christopher P.
    Landmesser, Ulf
    Luescher, Thomas F.
    Catapano, Alberico L.
    Ray, Kausik K.
    EUROPEAN HEART JOURNAL, 2018, 39 (27) : 2540 - 2545
  • [37] PCSK9 inhibitors and cardiovascular outcomes
    Steffens, Daniel
    Bramlage, Peter
    Scheeff, Celine
    Kasner, Mario
    Hassanein, Adel
    Friebel, Julian
    Rauch-Kroehnert, Ursula
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2020, 20 (01) : 35 - 47
  • [38] Can proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors regress coronary atherosclerotic plaque? A systematic review and meta-analysis
    Wu, Zijia
    Gao, Lulan
    Lin, Zhihai
    AMERICAN JOURNAL OF TRANSLATIONAL RESEARCH, 2023, 15 (01): : 452 - 465
  • [39] Association Between Industry Marketing Payments and Prescriptions for PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibitors in the United States
    Inoue, Kosuke
    Figueroa, Jose F.
    DeJong, Colette
    Tsugawa, Yusuke
    Orav, E. John
    Shen, Changyu
    Kazi, Dhruv S.
    CIRCULATION-CARDIOVASCULAR QUALITY AND OUTCOMES, 2021, 14 (05): : E007521
  • [40] Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) inhibitors and the risk for neurocognitive adverse events: A systematic review, meta-analysis and meta-regression
    Raccah, Bruria Hirsh
    Yanovsky, Alona
    Treves, Nir
    Rotshild, Victoria
    Renoux, Christel
    Danenberg, Haim
    Eliaz, Ran
    Matok, Ilan
    INTERNATIONAL JOURNAL OF CARDIOLOGY, 2021, 335 : 7 - 14
12345